University of Washington
Seattle, Washington, 98195, United States
NCT Number: NCT00122096
Surgery initiates a complex cascade of events involving the release of chemical compounds from nerve endings and damaged tissue which leads to an inflammatory and pain response. The purpose of this investigation is to measure various chemical mediators in the blood and cerebrospinal fluid, and to test the hypothesis that they will be decreased in patients treated with a COX-2 inhibitor.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Seattle, Washington, 98195, United States
Surgery initiates a complex cascade of events involving the release of nociceptive compounds from nerve endings and damaged tissue which leads to an inflammatory and hyperalgesic response. COX-2 inhibitors are often used for treating pain. This is a double-blind randomized study in surgical patients receiving a spinal drain for surgical purposes. The hypothesis is that valdecoxib will reach therapeutic concentrations in CSF, and will decrease plasma and CSF concentrations of inflammatory mediators. Subjects will receive valdecoxib 40 mg or placebo approximately 1 hr prior to surgery. Serial blood and CSF samples will be obtained. Valdecoxib and cytokine concentrations will be measured.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
University of Washington
Other
Preoperative Valdecoxib: CNS Penetration and Effects on Biochemical Markers of Pain and Sensitization
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07367503
Inflammation, Lymphocyte
Çanakkale, Center, Turkey (Türkiye)
View Trial DetailsNCT07398066
Brain Cancer, Brain Diseases
View Trial DetailsNCT05874050
Blood Pressure, Brain Diseases
Milan, Milano, Italy
View Trial DetailsNCT07199439
Hemorrhage, Neurosurgery
Riga, Latvia
View Trial Details